ArticleACS applied bio materials2026
Effect of Green Light-Mediated Corneal Cross-Linking on the Delivery of Rose Bengal and Vancomycin in Staphylococcus aureus-Infected Eyes.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rose Bengal (RB)-green light (GL) cross-linking (RGX), a phototherapy used to treat infectious keratitis, activates RB to generate reactive oxygen species (ROS), promoting bacterial killing and corneal strengthening through collagen cross-linking. Despite its promise, the way GL exposure alters RB behavior within the infected cornea remains poorly understood. This study investigates RB distribution and fluorescence changes following RGX in methicillin-susceptible Staphylococcus aureus-infected bovine corneas with denuded epithelium. Ex vivo RGX treatment resulted in a pronounced, infection-dependent loss of RB fluorescence. Infected corneas exposed to GL showed a 70-85% reduction in RB fluorescence across corneal tissues and aqueous humor, compared with non-illuminated RB-treated controls. Consistent with these findings, fluorescent RB was reduced from 63 to 19% dose/g of stroma with GL in infected eyes. In contrast, RGX-treated uninfected eyes showed increased RB fluorescence in the endothelium and aqueous humor, while stromal RB levels were similar to those in infected and uninfected eyes without RGX. RGX treatment did not affect corneal stromal integrity in infected or uninfected eyes, as assessed by biomechanical piercing forces and vancomycin distribution in the corneal stroma and endothelium. Vancomycin delivery ranged from 50 to 63% dose/g of stroma. To determine whether RB fluorescence loss could be reproduced under in vitro conditions, complementary studies were performed. GL exposure alone, or with live or heat-killed bacteria, did not result in RB fluorescence loss. However, replication of these experiments in the presence of bovine corneal stromal extract (BCSE) resulted in a decline in RB fluorescence, analogous to that observed in infected RGX-treated ex vivo eyes. This effect was attenuated by the addition of ROS scavengers, L-histidine, D-mannitol, and vitamin E, targeting Type I and Type II photochemical pathways. These findings suggest that ROS generated from GL-activated RB drive the infection- and tissue-dependent loss of RB fluorescence, without affecting corneal piercing force and vancomycin delivery to the corneal stroma or endothelium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.